Table 1.
Characteristic | No. (%) |
---|---|
Median Age, y (Range) | 33 (5-70) |
Sex | |
Male | 17 (65) |
Female | 9 (35) |
Disease Histologic Features | |
B lineage | 24 (92) |
Mixed lineage | 2 (8) |
Cytogenetic Risk Diagnosis | |
High risk | 9 (35) |
Intermediate risk | 11 (42) |
Unknown | 6 (23) |
Disease Status at Transplantation | |
Active disease | 3 (12) |
Remission | 23 (88) |
MRD present | 11 |
MRD absent | 15 |
Median Lines of Chemotherapy Before SCT (range),
5 Previous Allogeneic SCT |
3 (2-6) |
No. Courses IO | |
1 | 1 |
2 | 12 |
3 | 7 |
4 | 5 |
5 | 1 |
Median Mo to SCT (Range) | 19 (6-50) |
Transplantation Preparative Regimen | |
Busulfan-clofarabine | 11 (42) |
Busulfan-clofarabine-thiotepa | 4 (15) |
Fludarabine-melphalan | 4 (15) |
Fludarabine-melphalan-thiotepa | 4 (15) |
Cyclophosphamide or etoposide/TBI | 3 (13) |
Allotype | |
Matched-related donor | 9 (35) |
Matched-unrelated or 1 Ag mismatched | 16 (62) |
Mismatched cord | 1 (3) |
Abbreviations: Ag = antigen; IO = inotuzumab ozogamicin; MRD = minimal residual disease; SCT = stem cell transplantation; TBI = total body irradiation.